SEER Inquiry System - Question 20150065 Details

System Guide

Back to Search Results

SEER Inquiry System - Report

Produced: 05/27/2025 2:17 PM

Question 20150065

Export CSV Export PDF Print

Add to Report

Inquiry Details

References:

SEER*Rx

Question:

First course treatment/Chemotherapy/Drug category: Instructions in SEER*Rx state that Ibrance should be coded as chemotherapy. They also state that it is an endocrine-based therapy. Local physicians refer to Ibrance as hormone therapy. Please clarify.

Discussion:

Answer:

For cancer registry data collection, follow the instructions in SEER*Rx. It is important for all data collection to be consistent for reporting of cancer information.

Per the FDA: Ibrance is a chemotheraputic agent which was approved for use WITH Letrozole. Letrozole is a hormonal drug which may be why the physicians are stating the patient is receiving hormones. Ibrance should not be given alone to treat breast cancer. This drug will not be changing categories in SEER*Rx.

Cancer Site Category:

N/A

Data Item Category:

First course treatment, Chemotherapy

Other Category:

N/A

Year:

2015